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Table
Association betweenMPA total serum trough levels and toxicity and efﬁcacy
outcomes
1A) Toxicity outcome: Time-dependent Cox regression
Outcome N HR (95% CI) P-value
Time to neutrophils
 0.5 k/mcL
61 1.45 (0.65 - 3.25) 0.36
Time to platelets
 20 k/mcL
61 1.88 (0.82 - 4.30) 0.14
Time to TPN cessation 61 0.56 (0.20 - 1.58) 0.28
Time to CMV viremia 31 1.71 (0.38 - 7.59) 0.48
IB) Efﬁcacy outcome: Cumulative incidence of aGVHD by day 100
Outcome N Cumulative incidence
(95% CI)
P-value
aGVHD II-IV
Trough < 0.5 mcg/mL 15 0.67 (0.41 - 0.92) 0.29
Trough  0.5 mcg/mL 57 0.57(0.44 - 0.71)
aGVHD III-IV
Trough < 0.5 mcg/mL 15 0.27 (0.03 - 0.50) 0.12
Trough < 0.5 mcg/mL 57 0.11 (0.03 - 0.19)
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LZ patients vs. 13% of controls failed to achieve platelet
engraftment. The cumulative incidence of engraftment of
neutrophils plus platelets (using death without engraftment
as the competing risk) was lower in the LZ group (54%) vs.
the control group (83%) (P ¼ .005). Day 100 survival rates
were 58% for the LZ group vs. 92% for controls. Survival
probability is shown in Figure 1.
Conclusions: LZ does not signiﬁcantly affect time to
neutrophil engraftment, but does appear to prolong time to
platelet engraftment when compared to patients who did
not receive LZ. LZ should be used cautiously early after stem
cell transplantation.
Figure 1. Overall Survival
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Background: Mycophenolate mofetil (MMF) is frequently
combined with cyclosporine-A as immunosuppression in
unrelated donor CBT. Recent evidence suggests that thera-
peutic drug monitoring of mycophenolic acid (MPA), the
active metabolite of MMF, is advisable based on intra- and
inter-patient variability of MMF pharmacokinetics (PK).
Moreover, an increased incidence of acute graft-versus-host
disease (aGVHD) has been associated with low unbound
MPA AUCs in adult allograft recipients. This is highly rele-
vant in CBT as aGVHD is a leading cause of transplant-
related mortality. However, as AUCs are cumbersome,
a limited PK parameter such as MPA troughs would be ideal.
Also, the toxicity associated with MPA trough levels is not
established.
Methods: We evaluated the association between serial MPA
total serum trough levels in weeks 1-6 and transplant
outcomes in pediatric and adult double-unit CB recipients
transplanted 8/2009 to 6/2012 for hematologic malignancies
with 4-6/6 HLA-A,B antigen, DRB1 allele matched CB grafts.
To evaluate the association between trough levels andoutcomes, the trough levels were dichotomized into < 2
mcg/mL and  2 mcg/mL for toxicity (delayed engraftment,
gastrointestinal toxicity, viral infection), and < 0.5 mcg/mL
and  0.5 mcg/mL for efﬁcacy (aGVHD prevention) at each
time point.
Results: Seventy-four patients had MPA total serum trough
levels drawn weekly for 6 weeks. Sixty-one (82%) received
myeloablative (MA) conditioning and 31 (42%) were CMV
seropositive. Median trough levels by week were 0.9, 0.9,
0.6, 0.7, 0.9, and 1.3 mcg/mL. The change in trough levels
over time did not reach signiﬁcance (P ¼ .07). Recipients
of MA conditioning had lower MPA troughs than those
who received non-myeloablative conditioning (P ¼ .03). By
time-dependent Cox regression analysis, there was no
association between trough levels and toxicity as
measured by time to neutrophil and platelet recovery or
duration of total parenteral nutrition (TPN) in myeloa-
blative CBT recipients, or time to viremia in CMV sero-
positive patients (Table 1A). In a competing risk 2-week
landmark analysis, while differences between groups did
not reach signiﬁcance, it was notable that the incidence of
severe (grade III-IV) aGVHD was more than doubled in
those with a mean week 1 and 2 trough level < 0.5 mcg/
mL (Table 1B).
Conclusions: Analysis of this limited patient population
suggests that while MPA total serum trough levels appear to
have little effect on toxicity outcomes, the early post-trans-
plant (week 1-2) mean levels could be associated with the
risk of severe (grade III-IV) aGVHD. Further investigation in
a larger patient series is warranted.548
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